BiomX’s (PHGE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of BiomX (NYSEAMERICAN:PHGE) in a report issued on Wednesday morning,Benzinga reports. HC Wainwright currently has a $2.00 price objective on the stock.

BiomX Stock Up 3.1 %

NYSEAMERICAN PHGE opened at $0.76 on Wednesday. BiomX has a 12-month low of $0.48 and a 12-month high of $8.55. The stock has a market cap of $13.86 million, a price-to-earnings ratio of -0.24 and a beta of 1.31.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).